StockNews.com Begins Coverage on Agenus (NASDAQ:AGEN)

Stock analysts at StockNews.com began coverage on shares of Agenus (NASDAQ:AGEN) in a report issued on Wednesday. The firm set a “hold” rating on the biotechnology company’s stock.

Several other equities analysts have also issued reports on AGEN. HC Wainwright reissued a “buy” rating and set a $160.00 price objective on shares of Agenus in a report on Thursday, March 14th. B. Riley cut their price objective on shares of Agenus from $120.00 to $100.00 and set a “buy” rating on the stock in a report on Monday, March 18th.

Agenus Stock Performance

Shares of NASDAQ:AGEN opened at $6.30 on Wednesday. The firm has a market cap of $131.99 million, a PE ratio of -0.44 and a beta of 1.26. The firm’s 50 day simple moving average is $12.21 and its 200-day simple moving average is $14.41. Agenus has a one year low of $6.16 and a one year high of $42.60.

Agenus (NASDAQ:AGEN) last issued its earnings results on Thursday, March 14th. The biotechnology company reported ($2.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($2.20). The firm had revenue of $83.80 million for the quarter, compared to analyst estimates of $54.21 million. Equities research analysts predict that Agenus will post -8.2 EPS for the current fiscal year.

Insider Activity at Agenus

In other news, insider Garo H. Armen purchased 25,000 shares of the business’s stock in a transaction on Thursday, February 15th. The shares were acquired at an average cost of $13.00 per share, with a total value of $325,000.00. Following the completion of the acquisition, the insider now owns 31,298 shares of the company’s stock, valued at $406,874. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 4.80% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Agenus

Institutional investors and hedge funds have recently bought and sold shares of the company. Assenagon Asset Management S.A. lifted its stake in shares of Agenus by 3,008.8% during the fourth quarter. Assenagon Asset Management S.A. now owns 2,306,248 shares of the biotechnology company’s stock worth $1,909,000 after buying an additional 2,232,064 shares during the period. Swiss National Bank lifted its position in Agenus by 5.9% during the third quarter. Swiss National Bank now owns 690,100 shares of the biotechnology company’s stock valued at $780,000 after purchasing an additional 38,600 shares during the period. Citigroup Inc. lifted its position in Agenus by 41.0% during the third quarter. Citigroup Inc. now owns 707,213 shares of the biotechnology company’s stock valued at $799,000 after purchasing an additional 205,817 shares during the period. Exchange Traded Concepts LLC lifted its position in Agenus by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 107,019 shares of the biotechnology company’s stock valued at $89,000 after purchasing an additional 27,137 shares during the period. Finally, Principal Financial Group Inc. lifted its position in Agenus by 16.7% during the third quarter. Principal Financial Group Inc. now owns 107,291 shares of the biotechnology company’s stock valued at $121,000 after purchasing an additional 15,370 shares during the period. 61.46% of the stock is owned by hedge funds and other institutional investors.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.